The First Affiliated Hospital Of Zhengzhou University
Clinical trials sponsored by The First Affiliated Hospital Of Zhengzhou University, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo therapy aims to restore movement after stroke Results expected Sep 2026 (estimated)
- Can adding immunotherapy boost a stomach cancer combo? Results expected Nov 2026 (estimated)
- Minty colonoscopy rinse could boost cancer detection Results expected Dec 2026 (estimated)
- Peppermint power: could menthol ease colonoscopy cramps and spot more polyps? Results expected Dec 2026 (estimated)
- Could eating sooner after variceal ligation stop rebleeding? Results expected Jun 2027 (estimated)
-
Dual immunotherapy plus chemo before surgery: a new way to shrink stomach tumors?
Disease control Not yet recruitingResearchers are testing whether combining an experimental dual immunotherapy drug called QL1706 with standard chemotherapy (docetaxel, oxaliplatin and S-1) before surgery can help patients with locally advanced gastric or gastroesophageal junction cancer. The study enrolls 34 adu…
Phase 2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Triple therapy aims to stall pancreatic cancer
Disease control Not yet recruitingResearchers are testing whether combining retlirafusp alfa, famitinib, and AG chemotherapy (nab-paclitaxel plus gemcitabine) can slow cancer growth in people with unresectable pancreatic cancer. The trial enrolls about 88 adults with locally advanced or metastatic pancreatic duct…
Phase 2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for stroke patients: drug may restore brain function hours later
Disease control Not yet recruitingThis study tests a drug called pro-urokinase in people who have had a stroke in the back part of the brain (posterior circulation) and can be treated within 4.5 to 24 hours after symptoms start. About 586 participants will receive either the drug or a placebo, along with standard…
Phase 3 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Stroke drug could help hours later with MRI guidance
Disease control Not yet recruitingThis study tests whether the clot-busting drug tenecteplase can improve recovery in people with acute ischemic stroke when given 4.5 to 9 hours after symptoms start. It uses a special MRI pattern (DWI-FLAIR mismatch) to identify patients who might still benefit. About 564 adults …
Phase 3 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New hope for tough esophageal cancer: drug combo targets gene mutations
Disease control Not yet recruitingThis study tests whether a new combination of drugs (anlotinib hydrochloride plus benmelstobart) works better than the current standard treatment (toripalimab plus chemotherapy) for people with advanced esophageal cancer that has certain gene mutations. The trial will include 578…
Phase 3 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for advanced stomach cancer: experimental combo targets tumors after first-line failure
Disease control Not yet recruitingThis study tests a new drug called IBI363, which helps the immune system attack cancer cells, combined with other drugs (bevacizumab with or without nab-paclitaxel) as a second treatment for people with advanced stomach cancer. About 50 adults aged 18-75 whose cancer worsened aft…
Phase 1/2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for hard-to-treat ovarian cancer: drug duo shows promise in early trial
Disease control Not yet recruitingThis study tests a combination of two drugs (sacituzumab tirumotecan and bevacizumab) in 30 women with platinum-resistant recurrent ovarian cancer, a type that is very hard to treat. The goal is to see if the combo can shrink tumors better than current options. Participants must …
Phase 2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Can a standardized MRI accurately stage esophageal cancer?
Diagnosis Not yet recruitingThis trial aims to develop and validate a standardized MRI protocol for staging esophageal squamous cell carcinoma and assessing how well tumors respond to neoadjuvant therapy. About 500 adults scheduled for surgery will be enrolled, with some undergoing MRI before surgery and ot…
Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Diagnosis
Last updated Aug 20, 2026 00:00 UTC
-
Minty colonoscopy rinse could boost cancer detection
Diagnosis Not yet recruitingThis trial tests a special rinse solution containing menthol (from peppermint) and simethicone (a defoamer) during colonoscopy. The goal is to reduce muscle spasms and clear bubbles, giving doctors a better view to find precancerous polyps. About 500 adults undergoing colonoscopy…
Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
Peppermint power: could menthol ease colonoscopy cramps and spot more polyps?
Symptom relief Not yet recruitingThis study tests whether spraying a menthol solution into the colon during a colonoscopy can reduce painful muscle spasms and help doctors find more polyps. About 440 adults scheduled for a colonoscopy will take part. The goal is to see if this simple, natural compound can improv…
Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
New combo therapy aims to restore movement after stroke
Symptom relief Not yet recruitingThis study tests whether combining two therapies—blood flow restriction training (using a cuff to partially restrict blood flow during exercise) and brain stimulation (rTMS)—can improve arm and hand function in people who have weakness on one side after a stroke. 69 adults will b…
Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC